N6022 is a potent, selective, reversible, and efficacious S-Nitrosoglutathione reductase(GSNOR) inhibitor with IC₅₀ of 8 nM. IC50 & Target: IC50: 8 nM (GSNOR)^[2] In Vitro: N6022 shows concentration-dependent binding to rat plasma proteins. N6022 has more effect on ATP at lower drug concentrations (20 μM) than on GSH^[1]. N6022 binds in the GSNO substrate binding pocket like a competitive inhibitor with an IC₅₀ of 8 nM and a K_i of 2.5 nM. N6022 is uncompetitive with cofactors NAD⁺ and NADH^[2]. In Vivo: N6022 (50 mg/kg)-treated rats show a slight increase in the incidence of granulomas. In serum, N6022 remains in solution up to 5 mg/mL^[1].